PK10453, a Nonselective Platelet‐Derived Growth Factor Receptor Inhibitor, Prevents the Progression of Pulmonary Arterial Hypertension
Author:
Affiliation:
1. Bassett Medical CenterCooperstownNew YorkUSA
2. PulmokineRensselaerNew YorkUSA
3. MSP CorporationShoreviewMinnesotaUSA
4. University of MinnesotaMinneapolisMinnesotaUSA
5. Columbia Presbyterian Medical CenterNew YorkNew YorkUSA
Funder
National Institutes of Health
Publisher
Wiley
Subject
Pulmonary and Respiratory Medicine
Link
https://onlinelibrary.wiley.com/doi/pdf/10.1086/674881
Reference30 articles.
1. Platelet‐derived growth factor expression and function in idiopathic pulmonary arterial hypertension;Perros F;Am J Respir Crit Care Med,2008
2. Reversal of experimental pulmonary hypertension by PDGF inhibition;Schermuly RT;J Clin Invest,2005
3. Imatinib in pulmonary arterial hypertension patients with inadequate response to established therapy;Ghofrani HA;Am J Respir Crit Care Med,2010
4. Imatinib for the treatment of pulmonary arterial hypertension;Ghofrani HA;N Engl J Med,2005
5. Imatinib mesylate as add‐on therapy for pulmonary arterial hypertension: results of the randomized IMPRES study;Hoeper MM;Circulation,2013
Cited by 21 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. A novel PDGFR inhibitor WQ-C-401 prevents pulmonary vascular remodeling in rats with monocrotaline-induced pulmonary arterial hypertension;Experimental Cell Research;2024-08
2. Pharmacology and Rationale for Seralutinib in the Treatment of Pulmonary Arterial Hypertension;International Journal of Molecular Sciences;2023-08-10
3. AV-101, a novel inhaled dry-powder formulation of imatinib, in healthy adult participants: a phase 1 single and multiple ascending dose study;ERJ Open Research;2022-11-10
4. Platelet-derived growth factor (PDGF)-BB regulates the airway tone via activation of MAP2K, thromboxane, actin polymerisation and Ca2+-sensitisation;Respiratory Research;2022-07-15
5. Positioning imatinib for pulmonary arterial hypertension: A phase I/II design comprising dose finding and single‐arm efficacy;Pulmonary Circulation;2021-10
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3